ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0951

Epidermal IFNκ Increases Circulating and Cutaneous Monocytes in a C57/Bl6 Overexpression Mouse Model
Abstract Number: 1818

Epigenetic Profiling of Childhood-onset Lupus Reveals Distinct Epigenetic Clusters and Suggests Epigenetic Drivers of Disease Activity
Abstract Number: LB05

ER Stress-Induced ATP2A3 Drives Rheumatoid Arthritis via Activation of STING Signaling
Abstract Number: 2555

Ergonomic Modifications: Findings From the Making it WorkTM Systemic Sclerosis Program
Abstract Number: 2621

Erosive Hand Osteoarthritis Is Associated With Increased Risk of Incident Osteoporotic Fractures In Post-menopausal Women (QUALYOR Cohort)
Abstract Number: 2607

ERS-RA as a Tool for Cardiovascular Risk Prediction in Established Rheumatoid Arthritis: An External Validation
Abstract Number: 2586

Estimated Carrier Prevalence of HLA-B*58:01 Across Diverse Populations in the US and Globally
Abstract Number: 2085

Estimating the Association between Effusion-synovitis and Knee Pain in a Subset of Participants with Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)
Abstract Number: 0722

Estimating two-year risk of relapse in individuals with ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids
Abstract Number: 2580

Estrogen Modulates Neutrophil Biology: Implications for Autoimmunity
Abstract Number: 1281

Ethnic Disparities in Mental Health Screening, Diagnoses, and Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 0310

Evaluate Safety, Tolerability, and Pharmacodynamics of a Single Intra-Articular Injection of GNSC-001 Gene Therapy in Subjects with Knee Osteoarthritis: 12-month Results from DONATELLO
Abstract Number: 1932

Evaluating a Potential Cause of Excess Lung Cancer Mortality in RA: An Analysis of Chest CT Imaging Frequency in RA
Abstract Number: 0138

Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis
Abstract Number: 2041

Evaluating Biologic Effectiveness in Co-Occurring Dermatologic and Rheumatic Disease: A Systematic Review

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].